The principal hypothesis of this study is that two different maintenance regimens of
ticagrelor are safe, tolerable and associated with significant inhibition of erythrocyte
adenosine reuptake compared to clopidogrel in patients undergoing elective Percutaneous
Coronary Intervention (PCI) for stable Coronary artery disease (CAD).